John de Koning
John de Koning, Ph.D. is a General Partner at LSP, one of the largest European investment firms providing financing for life sciences and health care companies. LSP has raised over $3 billion and supported the growth of 300 companies since it started to invest in 1988. John joined LSP in 2006, was the driving force behind a large number of LSP’s investments and served on the Board of Directors of many of these companies, such as argenx (NASDAQ: ARGX), Merus (NASDAQ: MRUS), Prosensa (acquired by BioMarin), BMEYE (acquired by Edwards Lifesciences), ONWARD, eTheRNA, Aelin Therapeutics, XyloCor Therapeutics, Xilis, and VarmX.
John has a Master’s degree in Molecular Biology from the University of Utrecht and a Ph.D. in Oncology from the Erasmus University Rotterdam, both in the Netherlands. After obtaining his Ph.D., he received a prestigious fellowship from the Dutch Cancer Society to work at the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco. His results were published in numerous leading scientific journals, including Nature Genetics.